One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
From Vaccine Nationalism to Vaccine Equity — Finding a Path Forward
Ingrid T. Katz, M.D., M.H.S., Rebecca Weintraub, M.D., Linda-Gail Bekker, M.D., Ph.D., and Allan M. Brandt, Ph.D.
doi : 10.1056/NEJMp2103614
N Engl J Med 2021; 384:1281-1283
Vancomycin Infusion Reaction — Moving beyond “Red Man Syndrome”
Santiago Alvarez-Arango, M.D., S. Michelle Ogunwole, M.D., Thomas D. Sequist, M.D., M.P.H., Caitlin M. Burk, M.D., and Kimberly G. Blumenthal, M.D.
doi : 10.1056/NEJMp2031891
N Engl J Med 2021; 384:1283-1286
Beyond the Rubble of Lake Street — Minds in Crisis in a City in Crisis
Rebecca Grossman-Kahn, M.D.
doi : 10.1056/NEJMp2034060
N Engl J Med 2021; 384:1286-1287
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer, M.D., Boris Alekseev, M.D., Sun-Young Rha, M.D., Camillo Porta, M.D., Masatoshi Eto, M.D., Thomas Powles, M.D., Viktor Grünwald, M.D., Thomas E. Hutson, M.D., Evgeny Kopyltsov, M.D., Mar?a J. Méndez-Vidal, M.D., Vadim Kozlov, M.D., Anna Alyasova, M.D., Sung-Hoo Hong, M.D., Anil Kapoor, M.D., Teresa Alonso Gordoa, M.D., Jaime R. Merchan, M.D., Eric Winquist, M.D., Pablo Maroto, M.D., Jeffrey C. Goh, M.D., Miso Kim, M.D., Howard Gurney, M.B., B.S., Vijay Patel, M.D., Avivit Peer, M.D., Giuseppe Procopio, M.D., Toshio Takagi, M.D., Bohuslav Melichar, M.D., Frederic Rolland, M.D., Ugo De Giorgi, M.D., Shirley Wong, M.D., Jens Bedke, M.D., Manuela Schmidinger, M.D., Corina E. Dutcus, M.D., Alan D. Smith, M.D., Lea Dutta, M.D., Kalgi Mody, M.D., Rodolfo F. Perini, M.D., Dongyuan Xing, Ph.D., and Toni K. Choueiri, M.D. for the CLEAR Trial Investigators*
doi : 10.1056/NEJMoa2035716
N Engl J Med 2021; 384:1289-1300
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.
Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure
Olav L. Schj?rring, M.D., Ph.D., Thomas L. Klitgaard, M.D., Anders Perner, M.D., Ph.D., J?rn Wetterslev, M.D., Ph.D., Theis Lange, Ph.D., Martin Siegemund, M.D., Minna B?cklund, M.D., Ph.D., Frederik Keus, M.D., Jon H. Laake, M.D., Ph.D., Matthew Morgan, M.D., Ph.D., Katrin M. Thormar, M.D., Ph.D., S?ren A. Rosborg, M.D., Ph.D., Jannie Bisgaard, M.D., Ph.D., Annette E.S. Erntgaard, M.D., Anne-Sofie H. Lynnerup, M.D., Rasmus L. Pedersen, M.D., Elena Crescioli, M.D., Theis C. Gielstrup, M.D., Meike T. Behzadi, M.D., Lone M. Poulsen, M.D., Stine Estrup, M.D., Ph.D., Jens P. Laigaard, M.S., Cheme Andersen, M.D., Camilla B. Mortensen, R.N., Bj?rn A. Brand, M.D., Jonathan White, M.D., Ph.D., Inge-Lise Jarnvig, M.D., Ph.D., Morten H. M?ller, M.D., Ph.D., Lars Quist, M.D., Ph.D., Morten H. Bestle, M.D., Ph.D., Martin Sch?nemann-Lund, M.D., Maj K. Kamper, M.D., Mathias Hindborg, M.D., Alexa Hollinger, M.D., Caroline E. Gebhard, M.D., N?ria Zellweger, M.Sc., Christian S. Meyhoff, M.D., Ph.D., Mathias Hjort, M.D., Laura K. Bech, M.Sc., Thorbj?rn Gr?fte, M.D., Ph.D., Helle Bundgaard, M.D., Ph.D., Lars H.M. ?stergaard, M.D., Maria A. Thy?, M.D., Thomas Hildebrandt, M.D., Bülent Uslu, M.D., Christoffer G. S?lling, M.D., Ph.D., Nette M?ller-Nielsen, M.D., Anne C. Br?chner, M.D., Ph.D., Morten Borup, M.D., Ph.D., Marjatta Okkonen, M.D., Ph.D., Willem Dieperink, Ph.D., Ulf G. Pedersen, M.D., Anne S. Andreasen, M.D., Ph.D., Lone Buus, M.D., Tayyba N. Aslam, M.D., Robert R. Winding, M.D., Joerg C. Schefold, M.D., Stine B. Thorup, M.D., Susanne A. Iversen, M.D., Janus Engstr?m, B.Sc., Maj-Brit N. Kj?r, R.N., and Bodil S. Rasmussen, M.D., Ph.D. for the HOT-ICU Investigators*
doi : 10.1056/NEJMoa2032510
N Engl J Med 2021; 384:1301-1311
Patients with acute hypoxemic respiratory failure in the intensive care unit (ICU) are treated with supplemental oxygen, but the benefits and harms of different oxygenation targets are unclear. We hypothesized that using a lower target for partial pressure of arterial oxygen (Pao2) would result in lower mortality than using a higher target.
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality
David J.A. Jenkins, M.D., Ph.D., Mahshid Dehghan, Ph.D., Andrew Mente, Ph.D., Shrikant I. Bangdiwala, Ph.D., Sumathy Rangarajan, M.Sc., Kristie Srichaikul, M.D., Viswanathan Mohan, D.Sc., Alvaro Avezum, M.D., Rafael D?az, M.D., Annika Rosengren, M.D., Fernando Lanas, M.D., Patricio Lopez-Jaramillo, M.D., Wei Li, Ph.D., Aytekin Oguz, M.D., Rasha Khatib, Ph.D., Paul Poirier, M.D., Ph.D., Noushin Mohammadifard, Ph.D., Andrea Pepe, M.Sc., Khalid F. Alhabib, M.B., B.S., Jephat Chifamba, D.Phil., Afzal Hussein Yusufali, M.D., Romaina Iqbal, Ph.D., Karen Yeates, M.D., Khalid Yusoff, M.D., Noorhassim Ismail, M.D., Koon Teo, M.B., B.Ch., Sumathi Swaminathan, Ph.D., Xiaoyun Liu, Ph.D., Katarzyna Zato?ska, M.D., Rita Yusuf, Ph.D., and Salim Yusuf, D.Phil. for the PURE Study Investigators*
doi : 10.1056/NEJMoa2007123
N Engl J Med 2021; 384:1312-1322
Most data regarding the association between the glycemic index and cardiovascular disease come from high-income Western populations, with little information from non-Western countries with low or middle incomes. To fill this gap, data are needed from a large, geographically diverse population.
Sutimlimab in Cold Agglutinin Disease
Alexander R?th, M.D., Wilma Barcellini, M.D., Shirley D’Sa, M.D., Yoshitaka Miyakawa, M.D., Ph.D., Catherine M. Broome, M.D., Marc Michel, M.D., David J. Kuter, M.D., D.Phil., Bernd Jilma, M.D., Tor H.A. Tvedt, M.D., Ph.D., Joachim Fruebis, Ph.D., Xiaoyu Jiang, Ph.D., Stella Lin, Ph.D., Caroline Reuter, M.D., M.S.C.I., Jaime Morales-Arias, M.D., William Hobbs, M.D., Ph.D., and Sigbj?rn Berentsen, M.D., Ph.D.
doi : 10.1056/NEJMoa2027760
N Engl J Med 2021; 384:1323-1334
Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.
Vestibular Schwannomas
Matthew L. Carlson, M.D., and Michael J. Link, M.D.
doi : 10.1056/NEJMra2020394
N Engl J Med 2021; 384:1335-1348
Ulceroglandular Tularemia
Michael Buettcher, M.D., and Chiara Imbimbo, B.M.
doi : 10.1056/NEJMicm2031676
N Engl J Med 2021; 384:1349
Sunken Nose
Reza Zonozi, M.D., and John L. Niles, M.D.
doi : 10.1056/NEJMicm2031387
N Engl J Med 2021; 384:e52
Case 10-2021: A 70-Year-Old Man with Depressed Mood, Unsteady Gait, and Urinary Incontinence
Feyza Marouf, M.D., McKinley Glover, M.D., Bryce Wininger, M.D., and William T. Curry, M.D.
doi : 10.1056/NEJMcpc2027090
N Engl J Med 2021; 384:1350-1358
A Step Ahead in Metastatic Renal Cell Carcinoma
Alain Ravaud, M.D., Ph.D.
doi : 10.1056/NEJMe2101777
N Engl J Med 2021; 384:1360-1361
Effect of Oxygen Therapy on Mortality in the ICU
Paul J. Young, M.D., Ph.D.
doi : 10.1056/NEJMe2101538
N Engl J Med 2021; 384:1361-1363
Audio Interview: Antibody Responses to Natural Infection and Vaccination
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2105969
N Engl J Med 2021; 384:e65
Base Editing in Progeria
Jin-Soo Kim, Ph.D., and Maria Eriksson, Ph.D.
doi : 10.1056/NEJMcibr2100661
N Engl J Med 2021; 384:1364-1366
Escaping Catch-22 — Overcoming Covid Vaccine Hesitancy
Lisa Rosenbaum, M.D.
doi : 10.1056/NEJMms2101220
N Engl J Med 2021; 384:1367-1371
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
doi : 10.1056/NEJMc2101667
N Engl J Med 2021; 384:1372-1374
Sitagliptin for Prophylaxis of Acute Graft-versus-Host Disease
doi : 10.1056/NEJMc2101975
N Engl J Med 2021; 384:1374-1376
Pathophysiology of Inflammatory Bowel Diseases
doi : 10.1056/NEJMc2101562
N Engl J Med 2021; 384:1376-1378
The Rapid Rise in Cutaneous Melanoma Diagnoses
doi : 10.1056/NEJMc2101980
N Engl J Med 2021; 384:e54
